SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Hakkarainen Petri) "

Sökning: WFRF:(Hakkarainen Petri)

  • Resultat 1-2 av 2
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Hakkarainen, Petri, et al. (författare)
  • Diverging Nuclear Energy Paths : Swedish and Finnish Reactions to the Energiewende
  • 2012
  • Ingår i: RELP - A Journal of Renewable Energy Law and Policy. - Berlin : Lexxion. - 1869-4942. ; :4, s. 234-244
  • Tidskriftsartikel (refereegranskat)abstract
    • In Sweden and Finland, consideration of the German Energiewende is often reduced to the nuclear phase-out decision. It is precisely in the field of nuclear energy that the two Nordic countries and Germany have ended on different paths. This article charts the historical development of nuclear power in both Sweden and Finland in order to explain why they did not follow Germany in its post-Fukushima decision and whether changes in their respective positions are to be expected.
  •  
2.
  • Luukkonen, Panu K., et al. (författare)
  • Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease
  • 2020
  • Ingår i: JCI Insight. - : American Society for Clinical Investigation. - 2379-3708. ; 5:5
  • Tidskriftsartikel (refereegranskat)abstract
    • Carriers of the hydroxysteroid 17-β dehydrogenase 13 (HSD17B13) gene variant (rs72613567:TA) have a reduced risk of NASH and cirrhosis but not steatosis. We determined its effect on liver histology, lipidome, and transcriptome using ultra performance liquid chromatography-mass spectrometry and RNA-seq. In carriers and noncarriers of the gene variant, we also measured pathways of hepatic fatty acids (de novo lipogenesis [DNL] and adipose tissue lipolysis [ATL] using 2H2O and 2H-glycerol) and insulin sensitivity using 3H-glucose and euglycemic-hyperinsulinemic clamp) and plasma cytokines. Carriers and noncarriers had similar age, sex and BMI. Fibrosis was significantly less frequent while phospholipids, but not other lipids, were enriched in the liver in carriers compared with noncarriers. Expression of 274 genes was altered in carriers compared with noncarriers, consisting predominantly of downregulated inflammation-related gene sets. Plasma IL-6 concentrations were lower, but DNL, ATL and hepatic insulin sensitivity were similar between the groups. In conclusion, carriers of the HSD17B13 variant have decreased fibrosis and expression of inflammation-related genes but increased phospholipids in the liver. These changes are not secondary to steatosis, DNL, ATL, or hepatic insulin sensitivity. The increase in phospholipids and decrease in fibrosis are opposite to features of choline-deficient models of liver disease and suggest HSD17B13 as an attractive therapeutic target.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 1-2 av 2

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy